How a GS1 standard for IMP emerged?

Between April 2018 and March 2019, about sixty companies involved in clinical trials worked to develop a global standard Datamatrix allowing the IMP (IP) identification.


An initiative led by Sanofi, structured by GS1 and in which CREAPHARM CLINICAL SUPPLIES actively participated.


mind Health has discussed with Nicolas LE RUDULIER, Head of Innovations & Group Synergy Development & IT at CREAPHARM CLINICAL SUPPLIES, about our contribution in this standard suitable for clinical trials in a case study released on April, 20th: